Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 3 (March)

1. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios.
   Obstet Gynecol, 105(3): 642-3. [Abstract] [Full-text]
2. Ovarian malignancy in breast cancer patients with an adnexal mass.
   Obstet Gynecol, 105(3): 507-13. [Abstract] [Full-text]
3. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
   J Am Coll Surg, 200(3): 328-35. [Abstract] [Full-text]
4. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases.
   J Am Coll Surg, 200(3): 323-7. [Abstract] [Full-text]
5. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques.
   Lancet Oncol, 6(3): 145-57. [Abstract] [Full-text]
6. Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation.
   Biochem Biophys Res Commun, 329(2): 772-9. [Abstract] [Full-text]
7. The tumor suppressor DAL-1/4.1B modulates protein arginine N-methyltransferase 5 activity in a substrate-specific manner.
   Biochem Biophys Res Commun, 329(2): 522-30. [Abstract] [Full-text]
8. Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells.
   Biochem Biophys Res Commun, 329(2): 508-15. [Abstract] [Full-text]
9. Correlates of high-density mammographic parenchymal patterns by menopausal status in a rural population in Northern Greece.
   Eur J Cancer, 41(4): 590-600. [Abstract] [Full-text]
10. Early detection of breast and ovarian cancer in families with BRCA mutations.
    Eur J Cancer, 41(4): 549-54. [Abstract] [Full-text]
11. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?
    Eur J Cancer, 41(4): 508-15. [Abstract] [Full-text]
12. Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins.
    Biometrics, 61(1): 55-63. [Abstract] [Full-text]
13. Predictive markers in breast and other cancers: a review.
    Clin Chem, 51(3): 494-503. [Abstract] [Full-text]
14. Differential effects of messages for breast and cervical cancer screening.
    J Health Care Poor Underserved, 16(1): 42-52. [Abstract] [Full-text]
15. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    J Natl Cancer Inst, 97(5): 375-84. [Abstract] [Full-text]
16. Are breast density and bone mineral density independent risk factors for breast cancer?
    J Natl Cancer Inst, 97(5): 368-74. [Abstract] [Full-text]
17. Physician predictors of mammographic accuracy.
    J Natl Cancer Inst, 97(5): 358-67. [Abstract] [Full-text]
18. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
    JAMA, 293(9): 1073-81. [Abstract] [Full-text]
19. MRI accurately depicts underlying DCIS in a patient with Paget's disease of the breast without palpable mass and mammography findings.
    Jpn J Clin Oncol, 35(3): 149-53. [Abstract] [Full-text]
20. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Jpn J Clin Oncol, 35(3): 126-33. [Abstract] [Full-text]
21. Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer.
    Jpn J Clin Oncol, 35(3): 121-5. [Abstract] [Full-text]
22. Comparison of stearidonic acid and alpha-linolenic acid on PGE2 production and COX-2 protein levels in MDA-MB-231 breast cancer cell cultures.
    J Nutr Biochem, 16(3): 184-92. [Abstract] [Full-text]
23. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer.
    Biol Psychol, 69(1): 85-96. [Abstract] [Full-text]
24. Non-sentinel lymph node metastases in breast cancer patients with metastatic sentinel nodes.
    ANZ J Surg, 75(1): 27-31. [Abstract] [Full-text]
25. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
    Invest New Drugs, 23(2): 171-7. [Abstract] [Full-text]
26. p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha.
    Mol Cell Biol, 25(6): 2419-30. [Abstract] [Full-text]
27. Phyllodes tumors of the breast: the role of pathologic parameters.
    Am J Clin Pathol, 123(4): 529-40. [Abstract] [Full-text]
28. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.
    Am J Clin Pathol, 123(4): 541-6. [Abstract] [Full-text]
29. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
    Int J Biochem Cell Biol, 37(5): 1130-44. [Abstract] [Full-text]
30. Achieving substantial changes in eating behavior among women previously treated for breast cancer--an overview of the intervention.
    J Am Diet Assoc, 105(3): 382-91; quiz 488. [Abstract] [Full-text]
31. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
    Clin Cancer Res, 11(4): 1512-20. [Abstract] [Full-text]
32. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Clin Cancer Res, 11(4): 1500-3. [Abstract] [Full-text]
33. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
    Clin Cancer Res, 11(4): 1483-9. [Abstract] [Full-text]
34. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Clin Cancer Res, 11(4): 1380-5. [Abstract] [Full-text]
35. Disparities across the breast cancer continuum.
    Cancer Causes Control, 16(1): 35-44. [Abstract] [Full-text]
36. The effects of a National Breast and Cervical Cancer Early Detection Program on social disparities in breast cancer diagnosis and treatment in Massachusetts.
    Cancer Causes Control, 16(1): 27-33. [Abstract] [Full-text]
37. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial.
    J Altern Complement Med, 11(1): 21-7. [Abstract] [Full-text]
38. A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors.
    J Altern Complement Med, 11(1): 13-20. [Abstract] [Full-text]
39. Support of large breasts during tangential irradiation using a micro-shell and minimizing the skin dose--a pilot study.
    Med Dosim, 30(1): 31-5. [Abstract] [Full-text]
40. Interfractional dose variation due to seromas in radiotherapy of breast cancer.
    Med Dosim, 30(1): 8-11. [Abstract] [Full-text]
41. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Exp Cell Res, 304(2): 604-19. [Abstract] [Full-text]
42. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    J Steroid Biochem Mol Biol, 93(1): 25-34. [Abstract] [Full-text]
43. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    J Steroid Biochem Mol Biol, 93(1): 1-13. [Abstract] [Full-text]
44. Axillary vein abnormalities contribute to development of lymphoedema after surgery for breast cancer.
    Br J Surg, 92(3): 311-5. [Abstract] [Full-text]
45. Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo.
    Br J Surg, 92(3): 305-10. [Abstract] [Full-text]
46. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production.
    Cancer Immunol Immunother, 54(5): 468-76. [Abstract] [Full-text]
47. Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer.
    J Gene Med, 7(2): 145-57. [Abstract] [Full-text]
48. Psychological morbidity in women at increased risk of developing breast cancer: a controlled study.
    Psychooncology, 14(3): 196-203. [Abstract] [Full-text]
49. Online interaction. Effects of storytelling in an internet breast cancer support group.
    Psychooncology, 14(3): 211-20. [Abstract] [Full-text]
50. Who is not reassured following benign diagnosis of breast symptoms?
    Psychooncology, 14(3): 239-46. [Abstract] [Full-text]
51. Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression.
    Breast Cancer Res Treat, 89(3): 313-6. [Abstract] [Full-text]
52. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses.
    Breast Cancer Res Treat, 89(3): 309-12. [Abstract] [Full-text]
53. Improvement in intramammary sentinel lymph node removal using a novel prototype hand held probe during breast conservative surgery.
    Breast Cancer Res Treat, 89(3): 305-8. [Abstract] [Full-text]
54. The "portrait" of hereditary breast cancer.
    Breast Cancer Res Treat, 89(3): 297-304. [Abstract] [Full-text]
55. PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin.
    Breast Cancer Res Treat, 89(3): 289-96. [Abstract] [Full-text]
56. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment.
    Breast Cancer Res Treat, 89(3): 277-88. [Abstract] [Full-text]
57. Diagnosis, treatment and prognosis of internal mammary lymph node recurrence in breast cancer patients.
    Breast Cancer Res Treat, 89(3): 271-5. [Abstract] [Full-text]
58. Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans.
    Breast Cancer Res Treat, 89(3): 257-64. [Abstract] [Full-text]
59. Soy isoflavone supplementation elevates erythrocyte superoxide dismutase, but not plasma ceruloplasmin in postmenopausal breast cancer survivors.
    Breast Cancer Res Treat, 89(3): 251-5. [Abstract] [Full-text]
60. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat, 89(3): 243-9. [Abstract] [Full-text]
61. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
    Breast Cancer Res Treat, 89(3): 237-41. [Abstract] [Full-text]
62. Racial differences in the familial aggregation of breast cancer and other female cancers.
    Breast Cancer Res Treat, 89(3): 227-35. [Abstract] [Full-text]
63. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.
    Breast Cancer Res Treat, 89(3): 221-6. [Abstract] [Full-text]
64. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
    Breast Cancer Res Treat, 89(3): 215-20. [Abstract] [Full-text]
65. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
    Cancer Res, 65(5): 1961-72. [Abstract] [Full-text]
66. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.
    Cancer Res, 65(5): 1918-24. [Abstract] [Full-text]
67. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research.
    Cancer Res, 65(5): 1909-17. [Abstract] [Full-text]
68. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.
    Cancer Res, 65(5): 1904-8. [Abstract] [Full-text]
69. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
    Cancer Res, 65(5): 1858-67. [Abstract] [Full-text]
70. The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells.
    Cancer Res, 65(5): 1839-48. [Abstract] [Full-text]
71. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
    Cancer Res, 65(5): 1792-9. [Abstract] [Full-text]
72. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
    Cancer Res, 65(5): 1770-7. [Abstract] [Full-text]
73. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis.
    Cancer Res, 65(5): 1627-30. [Abstract] [Full-text]
74. Malignant fibrous histiocytoma of the female breast: a case report.
    Clin Imaging, 29(2): 134-7. [Abstract] [Full-text]
75. MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer.
    Int J Radiat Oncol Biol Phys, 61(4): 1243-50. [Abstract] [Full-text]
76. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
    Int J Radiat Oncol Biol Phys, 61(4): 1054-61. [Abstract] [Full-text]
77. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.
    Int J Radiat Oncol Biol Phys, 61(4): 1045-53. [Abstract] [Full-text]
78. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1.
    Biochem Biophys Res Commun, 329(3): 888-97. [Abstract] [Full-text]
79. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.
    Cancer, 103(6): 1122-8. [Abstract] [Full-text]
80. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina.
    Cancer, 103(6): 1114-21. [Abstract] [Full-text]
81. Reproducibility of cytologic atypia in repeat nipple duct lavage.
    Cancer, 103(6): 1129-36. [Abstract] [Full-text]
82. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Cancer, 103(6): 1147-53. [Abstract] [Full-text]
83. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast.
    Cancer, 103(6): 1137-46. [Abstract] [Full-text]
84. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
    Br J Cancer, 92(5): 857-66. [Abstract] [Full-text]
85. Primary tumour-vessel tumour-nodal tumour classification for patients with invasive ductal carcinoma of the breast.
    Br J Cancer, 92(5): 847-56. [Abstract] [Full-text]
86. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo.
    Clin Cancer Res, 11(5): 2047-52. [Abstract] [Full-text]
87. Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells.
    Clin Cancer Res, 11(5): 2038-46. [Abstract] [Full-text]
88. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer.
    Clin Cancer Res, 11(5): 1863-9. [Abstract] [Full-text]
89. B7-h4 is highly expressed in ductal and lobular breast cancer.
    Clin Cancer Res, 11(5): 1842-8. [Abstract] [Full-text]
90. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer.
    Clin Cancer Res, 11(5): 1722-32. [Abstract] [Full-text]
91. Screening for breast cancer.
    JAMA, 293(10): 1245-56. [Abstract] [Full-text]
92. Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes.
    Mol Cancer Res, 3(2): 71-7. [Abstract] [Full-text]
93. Does the theory of planned behavior mediate the effects of an oncologist's recommendation to exercise in newly diagnosed breast cancer survivors? Results from a randomized controlled trial.
    Health Psychol, 24(2): 189-97. [Abstract] [Full-text]
94. Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice.
    Proc Natl Acad Sci U S A, 102(10): 3772-6. [Abstract] [Full-text]
95. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures.
    Br J Cancer, 92(5): 955-60. [Abstract] [Full-text]
96. Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years.
    Br J Cancer, 92(5): 949-54. [Abstract] [Full-text]
97. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities.
    EMBO J, 24(5): 963-73. [Abstract] [Full-text]
98. Comparison of 1- and 2-year screening intervals for women undergoing screening mammography.
    Br J Cancer, 92(5): 961-6. [Abstract] [Full-text]
99. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques.
    Br J Cancer, 92(5): 906-12. [Abstract] [Full-text]
100. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
     Proc Natl Acad Sci U S A, 102(10): 3738-43. [Abstract] [Full-text]
101. Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation.
     FEBS Lett, 579(7): 1665-9. [Abstract] [Full-text]
102. Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study.
     J Clin Endocrinol Metab, 90(3): 1414-9. [Abstract] [Full-text]
103. Does hospital discharge policy influence sick-leave patterns in the case of female breast cancer?
     Health Policy, 72(1): 65-71. [Abstract] [Full-text]
104. Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development.
     Mol Nutr Food Res, 49(2): 93-100. [Abstract] [Full-text]
105. Radioimmunodetection and therapy of breast cancer.
     Semin Nucl Med, 35(2): 143-51. [Abstract] [Full-text]
106. Positron emission tomography and bone metastases.
     Semin Nucl Med, 35(2): 135-42. [Abstract] [Full-text]
107. Lymphatic mapping and sentinel node biopsy: a surgical perspective.
     Semin Nucl Med, 35(2): 129-34. [Abstract] [Full-text]
108. Update on detection of sentinel lymph nodes in patients with breast cancer.
     Semin Nucl Med, 35(2): 116-28. [Abstract] [Full-text]
109. Clinical applications of 99mTc-sestamibi scintimammography.
     Semin Nucl Med, 35(2): 100-15. [Abstract] [Full-text]
110. Evolving role of positron emission tomography in breast cancer imaging.
     Semin Nucl Med, 35(2): 84-99. [Abstract] [Full-text]
111. Thermoradiotherapy of the chest wall in locally advanced or recurrent breast cancer with marginal resection.
     Int J Hyperthermia, 21(2): 159-67. [Abstract] [Full-text]
112. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study.
     Eur J Cancer, 41(5): 779-85. [Abstract] [Full-text]
113. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer.
     Eur J Cancer, 41(5): 708-14. [Abstract] [Full-text]
114. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
     Eur J Cancer, 41(5): 694-701. [Abstract] [Full-text]
115. Estrogen receptor-alpha, bcl-2 and c-myc gene expression in fibroadenomas and adjacent normal breast: association with nodule size, hormonal and reproductive features.
     Steroids, 70(3): 153-60. [Abstract] [Full-text]
116. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes.
     Prostaglandins Leukot Essent Fatty Acids, 72(4): 267-72. [Abstract] [Full-text]
117. The use of the source-skin distance measuring bridge indeed reduces skin teleangiectasia after interstitial boost in breast conserving therapy.
     Radiother Oncol, 74(3): 323-30. [Abstract] [Full-text]
118. Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells.
     Biomacromolecules, 6(2): 1132-9. [Abstract] [Full-text]
119. Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis.
     J Clin Ultrasound, 33(3): 140-2. [Abstract] [Full-text]
120. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
     J Interferon Cytokine Res, 25(3): 144-51. [Abstract] [Full-text]
121. Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner.
     Mol Cell Biol, 25(7): 2808-18. [Abstract] [Full-text]
122. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
     Mol Cancer Ther, 4(3): 477-86. [Abstract] [Full-text]
123. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
     Mol Cancer Ther, 4(3): 435-42. [Abstract] [Full-text]
124. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.
     Mol Cancer Ther, 4(3): 361-8. [Abstract] [Full-text]
125. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.
     Arch Intern Med, 165(5): 552-8. [Abstract] [Full-text]
126. Patients' resistance to risk information in genetic counseling for BRCA1/2.
     Arch Intern Med, 165(5): 523-9. [Abstract] [Full-text]
127. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices.
     Arch Intern Med, 165(5): 516-20. [Abstract] [Full-text]
128. Risk of breast cancer after miscarriage or induced abortion: a Scottish record linkage case-control study.
     J Epidemiol Community Health, 59(4): 283-7. [Abstract] [Full-text]
129. Serum levels of hepatocyte growth factor in patients with breast cancer.
     Cancer Epidemiol Biomarkers Prev, 14(3): 715-7. [Abstract] [Full-text]
130. Urinary cadmium and serum levels of estrogens and androgens in postmenopausal Japanese women.
     Cancer Epidemiol Biomarkers Prev, 14(3): 705-8. [Abstract] [Full-text]
131. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
     Cancer Epidemiol Biomarkers Prev, 14(3): 699-704. [Abstract] [Full-text]
132. Association between mammographic breast density and breast cancer tumor characteristics.
     Cancer Epidemiol Biomarkers Prev, 14(3): 662-8. [Abstract] [Full-text]
133. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study.
     Cancer Epidemiol Biomarkers Prev, 14(3): 656-61. [Abstract] [Full-text]
134. Primary non-hodgkin lymphoma of breast in a patient with rectal carcinoma and magnetic resonance spectroscopic examination.
     Breast, 14(2): 169-74. [Abstract] [Full-text]
135. Bilateral axillary metastases of occult breast carcinoma: report of a case with a review of the literature.
     Breast, 14(2): 165-8. [Abstract] [Full-text]
136. A patient with occult breast cancer presenting with an axillary lymph node metastasis and a synchronous contralateral breast cancer.
     Breast, 14(2): 157-62. [Abstract] [Full-text]
137. Use of an interactive web-based questionnaire to evaluate a breast cancer website.
     Breast, 14(2): 153-6. [Abstract] [Full-text]
138. Why is carcinoma of the breast more frequent in the upper outer quadrant? A case series based on needle core biopsy diagnoses.
     Breast, 14(2): 151-2. [Abstract] [Full-text]
139. The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.
     Breast, 14(2): 142-50. [Abstract] [Full-text]
140. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer.
     Breast, 14(2): 136-41. [Abstract] [Full-text]
141. Breast conservation surgery--the surgeon's factor.
     Breast, 14(2): 131-5. [Abstract] [Full-text]
142. Oncological aspects of breast reconstruction.
     Breast, 14(2): 118-30. [Abstract] [Full-text]
143. Radiopaque coil insertion into breast cancers prior to neoadjuvant chemotherapy.
     Breast, 14(2): 108-17. [Abstract] [Full-text]
144. Seroma formation after axillary lymphadenectomy with and without the use of drains.
     Breast, 14(2): 103-7. [Abstract] [Full-text]
145. A population survival model for breast cancer.
     Breast, 14(2): 94-102. [Abstract] [Full-text]
146. The oligometastatic state in breast cancer: hypothesis or reality.
     Breast, 14(2): 87-93. [Abstract] [Full-text]
147. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria.
     Chem Biol Interact, 152(1): 49-58. [Abstract] [Full-text]
148. "Memory effect" in observer performance studies of mammograms.
     Acad Radiol, 12(3): 286-90. [Abstract] [Full-text]
149. High frequency of somatic missense mutation of BRCA2 in female breast cancer from Taiwan.
     Cancer Lett, 220(2): 177-84. [Abstract] [Full-text]
150. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
     Biochem Biophys Res Commun, 329(4): 1253-9. [Abstract] [Full-text]
151. GammaH2AX foci induced by gamma rays and 125idU decay.
     Int J Radiat Biol, 80(11): 895-903. [Abstract] [Full-text]
152. Fine-needle aspiration cytology of extramammary neoplasms metastatic to the breast.
     Diagn Cytopathol, 32(4): 193-7. [Abstract] [Full-text]
153. BetaPix-a enhances the activity of phospholipase Cgamma1 by binding SH3 domain in breast cancer.
     J Cell Biochem, 94(5): 1010-6. [Abstract] [Full-text]
154. Optimizing the treatment of metastatic breast cancer.
     Breast Cancer Res Treat, 89: S9-S15. [Abstract] [Full-text]
155. The future of breast cancer: the role of prognostic factors.
     Breast Cancer Res Treat, 89: S17-26. [Abstract] [Full-text]
156. Evolving treatment approaches for early breast cancer.
     Breast Cancer Res Treat, 89: S1-7. [Abstract] [Full-text]
157. Immunologic response to cryoablation of breast cancer.
     Breast Cancer Res Treat, 90(1): 97-104. [Abstract] [Full-text]
158. Comparison of cryopreservation and standard needle biopsy for gene expression profiling of human breast cancer specimens.
     Breast Cancer Res Treat, 90(1): 93-6. [Abstract] [Full-text]
159. Long-term outcomes of breast cancer patients after endoscopic axillary lymph node dissection: a prospective analysis of 52 patients.
     Breast Cancer Res Treat, 90(1): 85-91. [Abstract] [Full-text]
160. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration.
     Breast Cancer Res Treat, 90(1): 77-84. [Abstract] [Full-text]
161. Papillary lesions of the breast: a molecular progression?
     Breast Cancer Res Treat, 90(1): 71-6. [Abstract] [Full-text]
162. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
     Breast Cancer Res Treat, 90(1): 65-70. [Abstract] [Full-text]
163. The link between the insecticide heptachlor epoxide, estradiol, and breast cancer.
     Breast Cancer Res Treat, 90(1): 55-64. [Abstract] [Full-text]
164. Is family history related to preventive health behaviors and medical management in breast cancer patients?
     Breast Cancer Res Treat, 90(1): 47-54. [Abstract] [Full-text]
165. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure.
     Breast Cancer Res Treat, 90(1): 41-6. [Abstract] [Full-text]
166. Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance.
     Breast Cancer Res Treat, 90(1): 33-40. [Abstract] [Full-text]
167. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.
     Breast Cancer Res Treat, 90(1): 25-31. [Abstract] [Full-text]
168. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
     Breast Cancer Res Treat, 90(1): 15-23. [Abstract] [Full-text]
169. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
     Breast Cancer Res Treat, 90(1): 5-14. [Abstract] [Full-text]
170. Regional distribution of epifascial swelling and epifascial lymph drainage rate constants in breast cancer-related lymphedema.
     Lymphat Res Biol, 3(1): 3-15. [Abstract] [Full-text]
171. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer.
     J Natl Cancer Inst, 97(6): 448-56. [Abstract] [Full-text]
172. Ethnicity and breast cancer: factors influencing differences in incidence and outcome.
     J Natl Cancer Inst, 97(6): 439-48. [Abstract] [Full-text]
173. Risk of cardiac death after adjuvant radiotherapy for breast cancer.
     J Natl Cancer Inst, 97(6): 419-24. [Abstract] [Full-text]
174. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
     Biomaterials, 26(24): 5064-74. [Abstract] [Full-text]
175. Effect of histone H1 on the cytosolic calcium levels in human breast cancer MCF 7 cells.
     Life Sci, 76(22): 2631-41. [Abstract] [Full-text]
176. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
     Bioconjug Chem, 16(2): 354-60. [Abstract] [Full-text]
177. A variant of DNA polymerase beta is not cancer specific.
     J Invest Surg, 17(6): 327-31. [Abstract] [Full-text]
178. Decreased expression of e6-associated protein in breast and prostate carcinomas.
     Endocrinology, 146(4): 1707-12. [Abstract] [Full-text]
179. Covariate adjustment in family-based association studies.
     Genet Epidemiol, 28(3): 244-55. [Abstract] [Full-text]
180. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
     Cancer Gene Ther, 12(4): 350-8. [Abstract] [Full-text]
181. Progesterone but not estradiol 17beta potentiates local GH secretions by hormone-dependent breast cancer explants. An in vitro study.
     Exp Clin Endocrinol Diabetes, 113(2): 127-32. [Abstract] [Full-text]
182. Schwannoma of the breast: report of a case.
     Surg Today, 35(3): 238-42. [Abstract] [Full-text]
183. Isolated talus metastasis from breast carcinoma: a case report and review of the literature.
     Onkologie, 28(3): 141-3. [Abstract] [Full-text]
184. Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors.
     J Appl Physiol, 98(4): 1534-40. [Abstract] [Full-text]
185. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector.
     Mol Ther, 11(4): 523-30. [Abstract] [Full-text]
186. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
     J Clin Oncol, 23(9): 1951-61. [Abstract] [Full-text]
187. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis.
     J Clin Oncol, 23(9): 1941-50. [Abstract] [Full-text]
188. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.
     J Clin Oncol, 23(9): 1934-40. [Abstract] [Full-text]
189. In vivo absorbed dose measurements in mammography using a new real-time luminescence technique.
     Br J Radiol, 78(928): 328-34. [Abstract] [Full-text]
190. Comparison of full-field digital mammography and film-screen mammography: image quality and lesion detection.
     Br J Radiol, 78(928): 312-5. [Abstract] [Full-text]
191. A pilot study of a supervised group exercise programme as a rehabilitation treatment for women with breast cancer receiving adjuvant treatment.
     Eur J Oncol Nurs, 9(1): 56-63. [Abstract] [Full-text]
192. Involving women with breast cancer in the development of a patient information leaflet for anticipatory nausea and vomiting.
     Eur J Oncol Nurs, 9(1): 33-43. [Abstract] [Full-text]
193. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells.
     J Pharmacol Exp Ther, 313(1): 333-44. [Abstract] [Full-text]
194. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer.
     Int J Pharm, 293(1): 261-70. [Abstract] [Full-text]
195. Inhibition of tumor formation by snake venom disintegrin.
     Toxicon, 45(5): 661-9. [Abstract] [Full-text]
196. Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines.
     Exp Cell Res, 305(1): 83-98. [Abstract] [Full-text]
197. Therapy with women with metastatic breast cancer.
     Australas Psychiatry, 13(1): 50-3. [Abstract] [Full-text]
198. Breast intraoperative ultrasound: prospective study in 112 patients with impalpable lesions.
     ANZ J Surg, 75(3): 124-7. [Abstract] [Full-text]
199. Participation in the RACS sentinel node biopsy versus axillary clearance trial.
     ANZ J Surg, 75(3): 98-100. [Abstract] [Full-text]
200. Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors.
     Mod Pathol, 18(4): 591-7. [Abstract] [Full-text]
201. Skeletal health in postmenopausal survivors of early breast cancer.
     Int J Cancer, 114(6): 1010-5. [Abstract] [Full-text]
202. Early diagnosis of breast cancer by hair diffraction.
     Int J Cancer, 114(6): 969-72. [Abstract] [Full-text]
203. Use of antibiotics and risk of breast cancer.
     Am J Epidemiol, 161(7): 616-9. [Abstract] [Full-text]
204. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype.
     Cancer Res, 65(6): 2441-8. [Abstract] [Full-text]
205. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
     Cancer Res, 65(6): 2170-8. [Abstract] [Full-text]
206. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
     Cancer Res, 65(6): 2157-61. [Abstract] [Full-text]
207. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
     Cancer Res, 65(6): 2139-46. [Abstract] [Full-text]
208. Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness.
     Cancer Res, 65(6): 2125-9. [Abstract] [Full-text]
209. Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection.
     Biochem Biophys Res Commun, 330(1): 253-62. [Abstract] [Full-text]
210. Clotrimazole decreases human breast cancer cells viability through alterations in cytoskeleton-associated glycolytic enzymes.
     Mol Genet Metab, 84(4): 354-62. [Abstract] [Full-text]
211. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
     Eur J Surg Oncol, 31(3): 232-6. [Abstract] [Full-text]
212. Axillary recurrence in breast cancer.
     Eur J Surg Oncol, 31(3): 226-31. [Abstract] [Full-text]
213. Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study.
     Eur J Surg Oncol, 31(3): 221-5. [Abstract] [Full-text]
214. Cancer by negative heterosis: breast and ovarian cancer excess in hybrids of inbred ethnic groups.
     Med Hypotheses, 64(5): 1002-6. [Abstract] [Full-text]
215. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
     Med Hypotheses, 64(5): 997-1001. [Abstract] [Full-text]
216. Two staged breast reconstruction following prophylactic bilateral subcutaneous mastectomy.
     Br J Plast Surg, 58(3): 299-305. [Abstract] [Full-text]
217. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.
     Mol Pharmacol, 67(4): 1349-59. [Abstract] [Full-text]
218. BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters.
     Med Princ Pract, 14(2): 67-72. [Abstract] [Full-text]
219. Reproductive issues for women with BRCA mutations.
     J Natl Cancer Inst Monogr. [Abstract] [Full-text]
220. Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.
     Br J Cancer, 92(6): 1013-8. [Abstract] [Full-text]
221. The R72P P53 mutation is associated with familial breast cancer in Jewish women.
     Br J Cancer, 92(6): 1144-8. [Abstract] [Full-text]
222. K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.
     Br J Cancer, 92(6): 1098-103. [Abstract] [Full-text]
223. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice.
     Carcinogenesis, 26(4): 771-8. [Abstract] [Full-text]
224. Analysis of estrogen receptor alpha-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer.
     Mol Endocrinol, 19(4): 843-54. [Abstract] [Full-text]
225. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor.
     Mol Endocrinol, 19(4): 939-49. [Abstract] [Full-text]
226. Will cancer stem cells provide new therapeutic targets?
     Carcinogenesis, 26(4): 703-11. [Abstract] [Full-text]
227. The effect of experiential knowledge on construction of risk perception in hereditary breast/ovarian cancer.
     J Genet Couns, 14(1): 55-69. [Abstract] [Full-text]
228. Differences in individual approaches: communication in the familial breast cancer consultation and the effect on patient outcomes.
     J Genet Couns, 14(1): 43-53. [Abstract] [Full-text]
229. Screening for breast and cervical cancer in a large German city: participation, motivation and knowledge of risk factors.
     Eur J Public Health, 15(1): 70-7. [Abstract] [Full-text]
230. What information do breast cancer screening programmes provide to Italian women?
     Eur J Public Health, 15(1): 66-9. [Abstract] [Full-text]
231. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.
     Clin Cancer Res, 11(6): 2222-8. [Abstract] [Full-text]
232. Association of NCOA3 polymorphisms with breast cancer risk.
     Clin Cancer Res, 11(6): 2169-74. [Abstract] [Full-text]
233. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
     Clin Cancer Res, 11(6): 2163-8. [Abstract] [Full-text]
234. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
     Clin Cancer Res, 11(6): 2156-62. [Abstract] [Full-text]
235. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
     Clin Cancer Res, 11(6): 2111-22. [Abstract] [Full-text]
236. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
     Endocr Relat Cancer, 12(1): 75-92. [Abstract] [Full-text]
237. Identification of RAI3 as a therapeutic target for breast cancer.
     Endocr Relat Cancer, 12(1): 65-73. [Abstract] [Full-text]
238. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.
     Endocr Relat Cancer, 12(1): 1-17. [Abstract] [Full-text]
239. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
     Acta Oncol, 44(2): 134-41. [Abstract] [Full-text]
240. Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer.
     Acta Oncol, 44(2): 129-33. [Abstract] [Full-text]
241. A model for determining the effect of mammography service screening.
     Acta Oncol, 44(2): 120-8. [Abstract] [Full-text]
242. The reliability and accuracy of intraoperative imprint cytology of sentinel lymph nodes in breast cancer.
     Cytopathology, 16(2): 71-6. [Abstract] [Full-text]
243. Coping with appraised breast cancer risk among women with family histories of breast cancer.
     Res Nurs Health, 28(2): 144-58. [Abstract] [Full-text]
244. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival.
     J Pathol, 205(5): 585-91. [Abstract] [Full-text]
245. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
     J Pathol, 205(5): 577-84. [Abstract] [Full-text]
246. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma.
     Cancer, 103(7): 1323-9. [Abstract] [Full-text]
247. Immunohistochemically detected lymph node metastases from breast carcinoma: practical considerations about the new American Joint Committee on Cancer classification.
     Cancer, 103(7): 1319-22. [Abstract] [Full-text]
248. Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas.
     J Pathol, 205(5): 592-6. [Abstract] [Full-text]
249. No germline FH mutations in familial breast cancer patients.
     Eur J Hum Genet, 13(4): 506-9. [Abstract] [Full-text]
250. Breast epithelial cells in dermal angiolymphatic spaces: a manifestation of benign mechanical transport.
     Hum Pathol, 36(3): 310-3. [Abstract] [Full-text]
251. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
     Hum Pathol, 36(3): 250-61. [Abstract] [Full-text]
252. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.
     Eur J Nucl Med Mol Imaging, 32(3): 294-301. [Abstract] [Full-text]
253. Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer.
     Eur J Nucl Med Mol Imaging, 32(3): 286-93. [Abstract] [Full-text]
254. Significant expression of IGFBP2 in breast cancer compared with benign lesions.
     J Clin Pathol, 58(4): 361-6. [Abstract] [Full-text]
255. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
     Drug Resist Updat, 7(6): 325-31. [Abstract] [Full-text]
256. Depression and anxiety in women with early breast cancer: five year observational cohort study.
     BMJ, 330(7493): 702. [Abstract] [Full-text]
257. Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breast.
     Virchows Arch, 446(3): 305-9. [Abstract] [Full-text]
258. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
     Biophys Chem, 114(1): 1-12. [Abstract] [Full-text]
259. Ductal lavage in the high-risk patient.
     Am J Surg, 189(3): 340-1. [Abstract] [Full-text]
260. Influence of fibrin glue on seroma formation after breast surgery.
     Am J Surg, 189(3): 319-23. [Abstract] [Full-text]
261. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer.
     J Surg Oncol, 90(1): 26-30. [Abstract] [Full-text]
262. Site-select procedure for non-palpable breast lesions: feasibility study with a 15-mm cannula.
     J Surg Oncol, 90(1): 14-9. [Abstract] [Full-text]
263. Cryoablation and cryolocalization in the management of breast disease.
     J Surg Oncol, 90(1): 1-9. [Abstract] [Full-text]
264. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
     Br J Surg, 92(4): 429-34. [Abstract] [Full-text]
265. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions.
     Mol Cell Proteomics, 4(4): 492-522. [Abstract] [Full-text]
266. Clinical relevance of multiple sentinel nodes in patients with breast cancer.
     Br J Surg, 92(4): 438-42. [Abstract] [Full-text]
267. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
     Int J Cancer, 115(1): 19-35. [Abstract] [Full-text]
268. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast.
     Mol Cell Proteomics, 4(4): 555-69. [Abstract] [Full-text]
269. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients.
     Mol Cell Proteomics, 4(4): 483-91. [Abstract] [Full-text]
270. Inadequate treatment of symptomatic breast cancer.
     Br J Surg, 92(4): 422-8. [Abstract] [Full-text]
271. Contrast-enhanced dynamic MR imaging parameters and histological types of invasive ductal carcinoma of breast.
     Biomed Pharmacother, 59(3): 115-21. [Abstract] [Full-text]
272. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles.
     Nano Lett, 5(2): 331-8. [Abstract] [Full-text]
273. Assessing task "burden" of daily activities requiring upper body function among women following breast cancer treatment.
     Support Care Cancer, 13(4): 255-65. [Abstract] [Full-text]
274. Detection of apoptosis and drug resistance of human breast cancer cells to taxane treatments using quartz crystal microbalance biosensor technology.
     Assay Drug Dev Technol, 3(1): 77-88. [Abstract] [Full-text]
275. Localization of sentinel nodes in breast cancer: novel method and device to help pen marking of active nodes during gamma camera imaging.
     Phys Med Biol, 50(7): N49-54. [Abstract] [Full-text]
276. Novel functions of the phospholipase D2-Phox homology domain in protein kinase Czeta activation.
     Mol Cell Biol, 25(8): 3194-208. [Abstract] [Full-text]
277. Comparison of recall and cancer detection rates for immediate versus batch interpretation of screening mammograms.
     Radiology, 235(1): 31-5. [Abstract] [Full-text]
278. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks.
     Mol Cancer Res, 3(3): 151-62. [Abstract] [Full-text]
279. Breast cancer risk in a large cohort of female antidepressant medication users.
     Cancer Lett, 221(1): 61-5. [Abstract] [Full-text]
280. Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques.
     J Chromatogr B Analyt Technol Biomed Life Sci, 819(1): 59-66. [Abstract] [Full-text]
281. Computer-aided detection (CAD) in mammography: does it help the junior or the senior radiologist?
     Eur J Radiol, 54(1): 90-6. [Abstract] [Full-text]
282. Significance analysis of qualitative mammographic features, using linear classifiers, neural networks and support vector machines.
     Eur J Radiol, 54(1): 80-9. [Abstract] [Full-text]
283. Dynamic optical breast imaging: a new technique to visualise breast vessels: comparison with breast MRI and preliminary results.
     Eur J Radiol, 54(1): 72-9. [Abstract] [Full-text]
284. Precursor lesions of invasive breast cancer.
     Eur J Radiol, 54(1): 62-71. [Abstract] [Full-text]
285. Mammography of ductal carcinoma in situ of the breast: review of 909 cases with radiographic-pathologic correlations.
     Eur J Radiol, 54(1): 55-61. [Abstract] [Full-text]
286. Stellate images: anatomic and radiologic correlations.
     Eur J Radiol, 54(1): 37-54. [Abstract] [Full-text]
287. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.
     Curr Surg, 62(2): 253-7. [Abstract] [Full-text]
288. Perceived partner reactions to diagnosis and treatment of breast cancer: impact on psychosocial and psychosexual adjustment.
     J Consult Clin Psychol, 73(2): 300-11. [Abstract] [Full-text]
289. The effects of personal construct group therapy on breast cancer survivors.
     J Consult Clin Psychol, 73(2): 284-92. [Abstract] [Full-text]
290. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.
     Proc Natl Acad Sci U S A, 102(13): 4700-5. [Abstract] [Full-text]
291. Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model.
     Radiology, 235(1): 81-8. [Abstract] [Full-text]